{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T04:34:59Z","timestamp":1752986099564},"reference-count":54,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,22]]},"DOI":"10.7759\/cureus.52737","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T16:29:35Z","timestamp":1705940975000},"source":"Crossref","is-referenced-by-count":1,"title":["Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on Targeted Therapy"],"prefix":"10.7759","author":[{"given":"Mihaela","family":"Andreescu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Andreescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.14.1.333","article-title":"On immunological memory","volume":"14","author":"Zinkernagel RM","year":"1996","unstructured":"Zinkernagel RM, Bachmann MF, K\u00fcndig TM, Oehen S, Pirchet H, Hengartner H. On immunological memory. Annu Rev Immunol. 1996, 14:333-67. 10.1146\/annurev.immunol.14.1.333","journal-title":"Annu Rev Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf NK","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023, 23:90-105. 10.1038\/s41577-022-00732-1","journal-title":"Nat Rev Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1515\/rjim-2015-0010","article-title":"Multiple intestinal lymphoma","volume":"53","author":"Mastalier B","year":"2015","unstructured":"Mastalier B, Deaconescu V, Elaiah W, et al.. Multiple intestinal lymphoma. Rom J Intern Med. 2015, 53:73-8. 10.1515\/rjim-2015-0010","journal-title":"Rom J Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082417","article-title":"Allogeneic stem cell transplantation for adult T-cell leukemia\/lymphoma-Romanian experience","volume":"9","author":"Tanase AD","year":"2020","unstructured":"Tanase AD, Colita A, Craciun OG, et al.. Allogeneic stem cell transplantation for adult T-cell leukemia\/lymphoma-Romanian experience. J Clin Med. 2020, 9:10.3390\/jcm9082417","journal-title":"J Clin Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/636292","article-title":"HLA-G expression on blasts and tolerogenic cells in patients affected by acute myeloid leukemia","volume":"2014","author":"Locafaro G","year":"2014","unstructured":"Locafaro G, Amodio G, Tomasoni D, Tresoldi C, Ciceri F, Gregori S. HLA-G expression on blasts and tolerogenic cells in patients affected by acute myeloid leukemia. J Immunol Res. 2014, 2014:636292. 10.1155\/2014\/636292","journal-title":"J Immunol Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/tan.12898","article-title":"Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies","volume":"88","author":"Seliger B","year":"2016","unstructured":"Seliger B. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies. HLA. 2016, 88:213-20. 10.1111\/tan.12898","journal-title":"HLA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28338","article-title":"Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma","volume":"134","author":"del Campo AB","year":"2014","unstructured":"del Campo AB, Kyte JA, Carretero J, et al.. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer. 2014, 134:102-13. 10.1002\/ijc.28338","journal-title":"Int J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051155","article-title":"MHC class I regulation: the origin perspective","volume":"12","author":"Sznarkowska A","year":"2020","unstructured":"Sznarkowska A, Mikac S, Pilch M. MHC class I regulation: the origin perspective. Cancers (Basel). 2020, 12:10.3390\/cancers12051155","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.05.005","article-title":"Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system","volume":"21","author":"Pico de Coa\u00f1a Y","year":"2015","unstructured":"Pico de Coa\u00f1a Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med. 2015, 21:482-91. 10.1016\/j.molmed.2015.05.005","journal-title":"Trends Mol Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.944872","article-title":"Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond","volume":"13","author":"Pagliuca S","year":"2022","unstructured":"Pagliuca S, Gurnari C, Rubio MT, Visconte V, Lenz TL. Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. Front Immunol. 2022, 13:944872. 10.3389\/fimmu.2022.944872","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2500","article-title":"Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?","volume":"103","author":"Demanet C","year":"2004","unstructured":"Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, Ferrone S. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?. Blood. 2004, 103:3122-30. 10.1182\/blood-2003-07-2500","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00356.x","article-title":"Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts","volume":"98","author":"Masuda K","year":"2007","unstructured":"Masuda K, Hiraki A, Fujii N, et al.. Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Sci. 2007, 98:102-8. 10.1111\/j.1349-7006.2006.00356.x","journal-title":"Cancer Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-002-0296-0","article-title":"Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21","volume":"51","author":"Maleno I","year":"2002","unstructured":"Maleno I, L\u00f3pez-Nevot MA, Cabrera T, Salinero J, Garrido F. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother. 2002, 51:389-96. 10.1007\/s00262-002-0296-0","journal-title":"Cancer Immunol Immunother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0184-3","article-title":"Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases","volume":"4","author":"Ferns DM","year":"2016","unstructured":"Ferns DM, Heeren AM, Samuels S, Bleeker MC, de Gruijl TD, Kenter GG, Jordanova ES. Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases. J Immunother Cancer. 2016, 4:78. 10.1186\/s40425-016-0184-3","journal-title":"J Immunother Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0198-8859(01)00381-0","article-title":"Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon","volume":"63","author":"Brouwer RE","year":"2002","unstructured":"Brouwer RE, van der Heiden P, Schreuder GM, et al.. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol. 2002, 63:200-10. 10.1016\/s0198-8859(01)00381-0","journal-title":"Hum Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00147","article-title":"Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation","volume":"11","author":"Rovatti PE","year":"2020","unstructured":"Rovatti PE, Gambacorta V, Lorentino F, Ciceri F, Vago L. Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation. Front Immunol. 2020, 11:147. 10.3389\/fimmu.2020.00147","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00634-7","article-title":"HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy","volume":"18","author":"Anderson P","year":"2021","unstructured":"Anderson P, Aptsiauri N, Ruiz-Cabello F, Garrido F. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy. Cell Mol Immunol. 2021, 18:556-65. 10.1038\/s41423-021-00634-7","journal-title":"Cell Mol Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0198-8859(00)00097-5","article-title":"High frequency of altered HLA class I phenotypes in laryngeal carcinomas","volume":"61","author":"Cabrera T","year":"2000","unstructured":"Cabrera T, Salinero J, Fernandez MA, Garrido A, Esquivias J, Garrido F. High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Hum Immunol. 2000, 61:499-506. 10.1016\/s0198-8859(00)00097-5","journal-title":"Hum Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani M","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, et al.. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017, 376:2109-21. 10.1056\/NEJMoa1616288","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1101\/gr.165985.113","article-title":"Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival","volume":"24","author":"Brown SD","year":"2014","unstructured":"Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014, 24:743-50. 10.1101\/gr.165985.113","journal-title":"Genome Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.273","article-title":"HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance","volume":"27","author":"Campoli M","year":"2008","unstructured":"Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008, 27:5869-85. 10.1038\/onc.2008.273","journal-title":"Oncogene"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran E","year":"2016","unstructured":"Tran E, Robbins PF, Lu YC, et al.. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016, 375:2255-62. 10.1056\/NEJMoa1609279","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan N","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, et al.. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017, 171:1259-1271.e11. 10.1016\/j.cell.2017.10.001","journal-title":"Cell"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.02.009","article-title":"Prognostic factors and risk stratification in chronic lymphocytic leukemia","volume":"43","author":"Parikh SA","year":"2016","unstructured":"Parikh SA, Shanafelt TD. Prognostic factors and risk stratification in chronic lymphocytic leukemia. Semin Oncol. 2016, 43:233-40. 10.1053\/j.seminoncol.2016.02.009","journal-title":"Semin Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002899","article-title":"Deregulation of HLA-I in cancer and its central importance for immunotherapy","volume":"9","author":"Hazini A","year":"2021","unstructured":"Hazini A, Fisher K, Seymour L. Deregulation of HLA-I in cancer and its central importance for immunotherapy. J Immunother Cancer. 2021, 9:10.1136\/jitc-2021-002899","journal-title":"J Immunother Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3501","article-title":"The challenges of HLA class I loss in cancer immunotherapy: facts and hopes","volume":"28","author":"Aptsiauri N","year":"2022","unstructured":"Aptsiauri N, Garrido F. The challenges of HLA class I loss in cancer immunotherapy: facts and hopes. Clin Cancer Res. 2022, 28:5021-9. 10.1158\/1078-0432.CCR-21-3501","journal-title":"Clin Cancer Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2174","article-title":"The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma","volume":"12","author":"Paschen A","year":"2006","unstructured":"Paschen A, Arens N, Sucker A, et al.. The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res. 2006, 12:3297-305. 10.1158\/1078-0432.CCR-05-2174","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-008-0303-5","article-title":"Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy","volume":"60","author":"Carretero R","year":"2008","unstructured":"Carretero R, Romero JM, Ruiz-Cabello F, et al.. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics. 2008, 60:439-47. 10.1007\/s00251-008-0303-5","journal-title":"Immunogenetics"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604399","article-title":"Beta(2)microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients","volume":"98","author":"Shrout J","year":"2008","unstructured":"Shrout J, Yousefzadeh M, Dodd A, et al.. Beta(2)microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients. Br J Cancer. 2008, 98:1999-2005. 10.1038\/sj.bjc.6604399","journal-title":"Br J Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-010-0494-4","article-title":"Frequent loss of heterozygosity in the \u03b22-microglobulin region of chromosome 15 in primary human tumors","volume":"63","author":"Maleno I","year":"2011","unstructured":"Maleno I, Aptsiauri N, Cabrera T, Gallego A, Paschen A, L\u00f3pez-Nevot MA, Garrido F. Frequent loss of heterozygosity in the \u03b22-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics. 2011, 63:65-71. 10.1007\/s00251-010-0494-4","journal-title":"Immunogenetics"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.04.004","article-title":"The emerging role of soluble HLA-G in the control of chemotaxis","volume":"25","author":"Morandi F","year":"2014","unstructured":"Morandi F, Rouas-Freiss N, Pistoia V. The emerging role of soluble HLA-G in the control of chemotaxis. Cytokine Growth Factor Rev. 2014, 25:327-35. 10.1016\/j.cytogfr.2014.04.004","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0584-3","article-title":"Emerging topics and new perspectives on HLA-G","volume":"68","author":"Fainardi E","year":"2011","unstructured":"Fainardi E, Castellazzi M, Stignani M, et al.. Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci. 2011, 68:433-51. 10.1007\/s00018-010-0584-3","journal-title":"Cell Mol Life Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076023","article-title":"Soluble human leukocyte antigen-g5 activates extracellular signal-regulated protein kinase signaling and stimulates trophoblast invasion","volume":"8","author":"Guo Y","year":"2013","unstructured":"Guo Y, Lee CL, So KH, Gao J, Yeung WS, Yao Y, Lee KF. Soluble human leukocyte antigen-g5 activates extracellular signal-regulated protein kinase signaling and stimulates trophoblast invasion. PLoS One. 2013, 8:e76023. 10.1371\/journal.pone.0076023","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.796054","article-title":"HLA-G: too much or too little? Role in cancer and autoimmune disease","volume":"13","author":"Mart\u00edn-Villa JM","year":"2022","unstructured":"Mart\u00edn-Villa JM, Vaquero-Yuste C, Molina-Alejandre M, et al.. HLA-G: too much or too little? Role in cancer and autoimmune disease. Front Immunol. 2022, 13:796054. 10.3389\/fimmu.2022.796054","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm356","article-title":"HLA-G expression in human ovarian carcinoma counteracts NK cell function","volume":"18","author":"Lin A","year":"2007","unstructured":"Lin A, Yan WH, Xu HH, Gan MF, Cai JF, Zhu M, Zhou MY. HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann Oncol. 2007, 18:1804-9. 10.1093\/annonc\/mdm356","journal-title":"Ann Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0515-7","article-title":"Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer","volume":"18","author":"Xu Y","year":"2021","unstructured":"Xu Y, Xiang Z, Alnaggar M, et al.. Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021, 18:427-39. 10.1038\/s41423-020-0515-7","journal-title":"Cell Mol Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-011-0632-7","article-title":"Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer","volume":"68","author":"Lesport E","year":"2011","unstructured":"Lesport E, Baudhuin J, Sousa S, et al.. Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cell Mol Life Sci. 2011, 68:3385-99. 10.1007\/s00018-011-0632-7","journal-title":"Cell Mol Life Sci"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300438","article-title":"Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses","volume":"192","author":"Naji A","year":"2014","unstructured":"Naji A, Menier C, Morandi F, et al.. Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses. J Immunol. 2014, 192:1536-46. 10.4049\/jimmunol.1300438","journal-title":"J Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1221535110","article-title":"Exocytosis acts as a modulator of the ILT4-mediated inhibition of neutrophil functions","volume":"110","author":"Baudhuin J","year":"2013","unstructured":"Baudhuin J, Migraine J, Faivre V, Loumagne L, Lukaszewicz AC, Payen D, Favier B. Exocytosis acts as a modulator of the ILT4-mediated inhibition of neutrophil functions. Proc Natl Acad Sci U S A. 2013, 110:17957-62. 10.1073\/pnas.1221535110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa D","year":"2013","unstructured":"Brusa D, Serra S, Coscia M, et al.. The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013, 98:953-63. 10.3324\/haematol.2012.077537","journal-title":"Haematologica"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1159\/000353757","article-title":"HLA-G expression as a prognostic indicator in B-cell chronic lymphocytic leukemia","volume":"132","author":"Attia MA","year":"2014","unstructured":"Attia MA, Nosair NA, Gawally A, Elnagar G, Elshafey EM. HLA-G expression as a prognostic indicator in B-cell chronic lymphocytic leukemia. Acta Haematol. 2014, 132:53-8. 10.1159\/000353757","journal-title":"Acta Haematol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.165","article-title":"Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo DJ","year":"2013","unstructured":"DiLillo DJ, Weinberg JB, Yoshizaki A, et al.. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2013, 27:170-82. 10.1038\/leu.2012.165","journal-title":"Leukemia"},{"key":"ref43","article-title":"Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia","volume":"39","author":"Parmar S","year":"2014","unstructured":"Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P T. 2014, 39:483-519.","journal-title":"P T"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.08.006","article-title":"Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia","volume":"72","author":"Manukyan G","year":"2018","unstructured":"Manukyan G, Turcsanyi P, Mikulkova Z, et al.. Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia. Leuk Res. 2018, 72:113-9. 10.1016\/j.leukres.2018.08.006","journal-title":"Leuk Res"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi F","year":"2015","unstructured":"Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015, 126:573-81. 10.1182\/blood-2015-03-567388","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin Q","year":"2017","unstructured":"Yin Q, Sivina M, Robins H, et al.. Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia. J Immunol. 2017, 198:1740-7. 10.4049\/jimmunol.1601190","journal-title":"J Immunol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib-findings from an investigator-initiated phase II study","volume":"22","author":"Niemann CU","year":"2016","unstructured":"Niemann CU, Herman SE, Maric I, et al.. Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib-findings from an investigator-initiated phase II study. Clin Cancer Res. 2016, 22:1572-82. 10.1158\/1078-0432.CCR-15-1965","journal-title":"Clin Cancer Res"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013926","article-title":"Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib","volume":"139","author":"Purroy N","year":"2022","unstructured":"Purroy N, Tong YE, Lemvigh CK, et al.. Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood. 2022, 139:2252-6. 10.1182\/blood.2021013926","journal-title":"Blood"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long M","year":"2017","unstructured":"Long M, Beckwith K, Do P, et al.. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017, 127:3052-64. 10.1172\/JCI89756","journal-title":"J Clin Invest"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.15","article-title":"NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G","volume":"22","author":"Maki G","year":"2008","unstructured":"Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia. 2008, 22:998-1006. 10.1038\/leu.2008.15","journal-title":"Leukemia"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095281","article-title":"HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism","volume":"99","author":"Rizzo R","year":"2014","unstructured":"Rizzo R, Audrito V, Vacca P, et al.. HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica. 2014, 99:888-96. 10.3324\/haematol.2013.095281","journal-title":"Haematologica"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.2174\/187153011794982059","article-title":"HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy","volume":"11","author":"Yan WH","year":"2011","unstructured":"Yan WH. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocr Metab Immune Disord Drug Targets. 2011, 11:76-89. 10.2174\/187153011794982059","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02917","article-title":"Ig-like transcript 2 (ILT2) blockade and lenalidomide restore NK cell function in chronic lymphocytic leukemia","volume":"9","author":"Villa-\u00c1lvarez M","year":"2018","unstructured":"Villa-\u00c1lvarez M, Sordo-Bahamonde C, Lorenzo-Herrero S, et al.. Ig-like transcript 2 (ILT2) blockade and lenalidomide restore NK cell function in chronic lymphocytic leukemia. Front Immunol. 2018, 9:2917. 10.3389\/fimmu.2018.02917","journal-title":"Front Immunol"},{"key":"ref54","article-title":"HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma","volume":"18","author":"Komohara Y","year":"2007","unstructured":"Komohara Y, Harada M, Ishihara Y, et al.. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncol Rep. 2007, 18:1463-8.","journal-title":"Oncol Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/222028-immune-evasion-through-human-leukocyte-antigen-implications-and-its-impact-on-targeted-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:25Z","timestamp":1707509545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/222028-immune-evasion-through-human-leukocyte-antigen-implications-and-its-impact-on-targeted-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":54,"URL":"https:\/\/doi.org\/10.7759\/cureus.52737","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}